Cantargia reports treatment of first non-squamous non-small cell lung cancer patient in new arm of CANFOUR study
Cantargia AB today reported that the first patient in the new non-squamous non-small cell lung cancer (NSCLC) therapy arm of the CANFOUR study has received treatment with nadunolimab and chemotherapy. Interim clinical data has shown encouraging efficacy in patients with non-squamous histology, the largest NSCLC subgroup. Up to 40 patients will be treated with nadunolimab and carboplatin/pemetrexed and recruitment is expected to take 12-15 months. In parallel, preparations are ongoing for a randomized trial in this patient group with an anticipated start in early 2023.Nadunolimab, an